A recent phase 3 trial on oral peanut immunotherapy suggests positive results and is one step closer to FDA approval.
This study was recently published in The New England Journal of Medicine. It showed that 67.2% of patients between ages 4 and 17 years old were able to ingest a dose of 600 mg or more of peanut protein after receiving the active treatment, AR101, compared to 4% of patients who received the placebo. This effect was not seen in patients 18 years or older.
Currently, this therapy is on the “fast-track” for approval by the F.D.A. Although this is not a cure for peanut allergy, this may prevent a severe reaction after accidental ingestion. A link to the article is below: